Comparative Pharmacology
Head-to-head clinical analysis: MYFORTIC versus ZORTRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYFORTIC versus ZORTRESS.
MYFORTIC vs ZORTRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), thereby depleting guanosine nucleotides in T and B lymphocytes, suppressing their proliferation and antibody production.
Inhibits mammalian target of rapamycin (mTOR) by binding to FKBP-12, blocking cell cycle progression from G1 to S phase, thereby suppressing cytokine-driven T-cell proliferation.
720 mg orally twice daily, on an empty stomach, 1 hour before or 2 hours after meals.
1.5 mg orally twice daily, administered with cyclosporine and corticosteroids.
None Documented
None Documented
Terminal elimination half-life is approximately 12-18 hours (mean 17 hours) in healthy volunteers; longer in hepatic impairment (up to 40 hours).
Terminal elimination half-life is approximately 10-15 hours in renal transplant patients. In de novo liver transplant patients, half-life is ~13 hours. The effective half-life supports twice-daily dosing.
Primarily renal (approximately 95% as metabolites, <3% as unchanged drug); biliary/fecal excretion accounts for <5%.
Primarily fecal (~78%) with <2.5% excreted unchanged in urine. Small amount via biliary elimination.
Category C
Category C
Immunosuppressant
Immunosuppressant